1980
General Progress in Clinical Chemotherapy of Advanced Disease
Muggia F, Henney J, DeVita V. General Progress in Clinical Chemotherapy of Advanced Disease. Recent Results In Cancer Research 1980, 74: 1-7. PMID: 7003657, DOI: 10.1007/978-3-642-81488-4_1.Peer-Reviewed Original ResearchConceptsAggressive systemic treatmentMinimal residual diseaseTumor cell cytotoxicityAdvanced diseaseImmunologic factorsSystemic treatmentLocal therapyAdvanced cancerTumor burdenResidual diseaseTumor controlCurative approachLocoregional drug deliveryClinical chemotherapySuccessful chemotherapyEffective drugsDrug pharmacologyCell cytotoxicityInfectious diseasesDiseaseChemotherapyCancerCurrent resultsCellular heterogeneityTherapy
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvival